For oral communications (including slides of lectures and posters), click here or scroll until after the publications.

See also my Google scholar

Selected publications

Artificial intelligence and mechanistic modeling for clinical decision making in oncology
S. Benzekry
Clinical Pharmacology and Therapeutics,, Volume 108, Issue 3, pp.471-486, 2020


Machine learning and mechanistic modeling for prediction of metastatic relapse in breast cancer
C. Nicolo, C. Perier, M. Prague, G. MacGrogan, O. Saut, S. Benzekry
JCO: Clinical Cancer Informatics, Volume 4, pp. 259-274, bioRxiv, 2020


Contributions in Mathematical Oncology: When Theory Meets Reality
HDR (Habilitation à diriger des recherches) thesis, defended November 13th, 2017


Modeling spontaneous metastasis following surgery: an in vivo-in silico approach
S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, J.M.L. Ebos
Cancer Research, Volume 76, Issue 3, pp. 535-547, hal, 2016


Mathematical modeling of tumor-tumor distant interactions supports a systemic anti-proliferative control of tumor growth
S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, P. Hahnfeldt
Cancer Research, Volume 77, Issue 18, pp.5183-5193, 2017


Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy and S. Benzekry
Scientific Reports, Volume 9, Issue 1, 13018, bioRxiv, hal, 2019


Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth
S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky, P. Hahnfeldt
PLoS Computational Biology, Volume 10, Issue 8, e1003800, 2014


Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
D.C. Imbs*, R. El Cheikh*, A. Boyer, J. Ciccolini, C. Mascaux, B. Lacarelle, F. Barlesi, D. Barbolosi and S. Benzekry, * = equal contribution
CPT Pharmacometrics Syst Pharmacol, Volume 7, Issue 1, pp. 42-50, hal, 2018


Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, C. Poignard, J. ML Ebos, S. Benzekry
PLoS Computational Biology, Volume 16, Issue 2, e1007178, bioRxiv, 2020


Computational modelling of metastasis development in renal cell carcinoma
E. Baratchart, S. Benzekry*, A. Bikfalvi*, T. Colin*, L.S. Cooley, R. Pineau, E. Ribot, O. Saut, W. Souleyreau, * = joint supervising authors
PLoS Computational Biology, Volume 11, Issue 11, e1004626, hal, 2015


Journal articles

    2022


  1. Identifiability analysis of a mechanistic model for the time to distant metastatic relapse and its application to renal cell carcinoma
    A. Alvarez-Arenas, W. Souleyreau, A. Emanuelli, L.S. Cooley, JC Bernhard, A. Bikfalvi, and S. Benzekry
    to appear in PLoS Computational Biology, bioRxiv, 2022

  2. Tumor growth monitoring in breast cancer xenografts: a good technique for a strong ethic
    A. Rodallec, C. Vaghi, J. Ciccolini, R. Fanciullino, and S. Benzekry
    in revision in PLoS One, 2022

  3. Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
    B. K. Schneider, S. Benzekry, J. P. Mochel submitted, medRxiv, 2022

  4. Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells
    Y. Shi, M. Dolan, M. Mastri, J. W. Hill, A. Dommer, S. Benzekry, K. Eng, J. Ebos
    submitted, bioRxiv, 2022

  5. Macro-scale models for fluid flow in tumour tissues: impact of microstructure properties
    C. Vaghi, R. Fanciullino, S. Benzekry, C. Poignard
    Journal of Mathematical Biology, Volume 84, Issue 27, bioRxiv, 2022


    6. 2021


  6. Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data
    S. Benzekry, M. Grangeon, M. Karlsen, M. Alexa, I. Bicalho-Frazeto, S. Chaleat, P. Tomasini, D. Barbolosi, F. Barlesi, L. Greillier
    Cancers, Volume 5, pp. 81-90, medRxiv, 2021

  7. Development and Validation of a Prediction Model of Overall Survival in High-Risk Neuroblastoma Using Mechanistic Modeling of Metastasis
    S. Benzekry, C. Sentis, C. Coze, L. Tessonnier, N. André
    JCO: Clin Cancer Informatics, Volume 5, pp. 81-90, medRxiv, 2021

  8. Asymptotic analysis of a biphase tumor fluid flow. The weak coupling case
    C. Vaghi, S. Benzekry, Clair Poignard
    Apllied Mathematics and Computation, 413, 126635, aRxiv, 2021

  9. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
    L. Cooley, J. Rudewicz, W. Souleyreau, A. Emmanuelli, A. Alvarez-Arenas, K. Clarke, F. Falciani, M. Dufies, D. Lambrechts, E. Modave, D. Chalopin-Fillot, R. Pineau, D. Ambrosetti, J-C Bernhard, A. Ravaud, S. Negrier, J-M Ferrero, G. Pages, S. Benzekry, M. Nikolski, A. Bikfalvi Molecular Cancer, 20, bioRxiv, 2021


    10. 2020



  10. Artificial intelligence and mechanistic modeling for clinical decision making in oncology
    S. Benzekry
    Clinical Pharmacology and Therapeutics, Volume 108, Issue 3, pp.471-486, 2020

  11. Machine learning and mechanistic modeling for prediction of metastatic relapse in breast cancer
    C. Nicolo, C. Perier, M. Prague, G. MacGrogan, O. Saut, S. Benzekry
    JCO: Clinical Cancer Informatics, Volume 4, pp. 259-274, bioRxiv, 2020

  12. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
    C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, C. Poignard, J. ML Ebos, S. Benzekry
    PLoS Computational Biology, Volume 16, Issue 2, e1007178, bioRxiv, 2020

  13. Mechanistic learning for combinatorial strategies with immuno-oncology drugs: can model-informed designs help investigators?
    J. Ciccolini, D. Barbolosi, N. André, F. Barlesi, S. Benzekry
    JCO: Precision Oncology, , Volume 4, pp. 486-491, 2020


    14. 2019



  14. Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
    M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy and S. Benzekry
    Scientific Reports, Volume 9, Issue 1, 13018, bioRxiv, hal, 2019

  15. Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology
    A. Rodallec, R. Fanciullino, S. Benzekry, J. Ciccolini, EORTC PAMM group
    Anticancer Research, Volume 39, Issue 7, p. 3419-3422, hal, 2019

  16. Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non-Small Cell Lung Cancer
    B. K Schneider, A. Boyer, J. Ciccolini, F. Barlesi, K. Wang, S. Benzekry* and J. P Mochel*, * = joint senior authors
    CPT Pharmacometrics Syst Pharmacol, Volume 25, hal, 2019

  17. CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
    J. P Mochel, S. C Ekker, C. M Johannes, A. E Jergens, K. Allenspach, A. Bourgois-Mochel, M. Knouse, S. Benzekry, W. Wierson, A. K LeBlanc, S. S Kenderian
    AAPS J, Volume 21, Issue 3, p.50, hal, 2019


    18. 2018



  18. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
    A. Rodallec, G. Sicard, R. Fanciullino, S. Benzekry, B. Lacarelle, G. Milano, J. Ciccolini
    Expert Opin Drug Met, Volume 14, Issue 11, p. 1139-1147, 2018

  19. Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
    D.C. Imbs*, R. El Cheikh*, A. Boyer, J. Ciccolini, C. Mascaux, B. Lacarelle, F. Barlesi, D. Barbolosi and S. Benzekry, * = equal contribution
    CPT Pharmacometrics Syst Pharmacol, Volume 7, Issue 1, pp. 42-50, hal, 2018

  20. Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach
    M. Benguigui, D. Alishekevitz, M. Timaner, D. Shechter, Z. Raviv, S. Benzekry*, Y. Shaked*, * = joint senior authors
    Oncotarget, Volume 9, pp.2574-2590, 2018

  21. Pharmacokinetics of nanoparticles in oncology: clues for anticipating interpatient variability
    R. Fanciullino, S. Benzekry, B. Lacarelle, J. Ciccolini, A. Rodallec
    Critical Reviews in Oncology/Hematology, Volume 129, pp. 1-12, hal, 2018


    22. 2017



  22. Mathematical modeling of tumor-tumor distant interactions supports a systemic control of tumor growth
    S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, P. Hahnfeldt
    Cancer Research, Volume 77, Issue 18, pp.5183-5193, 2017

  23. Non-Standard Radiotherapy Fractionations Delay the Time to Malignant Transformation of Low-Grade Gliomas
    A. Henares-Molina, S. Benzekry, P.C. Lara, M. Garcia-Rojo, V.M. Perez-Garcia and A. Martinez-Gonzalez
    PLoS One, Volume 12, Issue 6, e0178552, hal, 2017

  24. Model Driven Optimization of Antiangiogenics + Cytotoxics Combination: Application to Breast Cancer Mice Treated with Bevacizumab + Paclitaxel Doublet Leads to Reduced Tumor Growth and Fewer Metastasis
    S. Mollard, J. Ciccolini, D.C. Imbs, R. El Cheikh, D. Barbolosi, S. Benzekry
    Oncotarget, Volume 5, 10.18632/oncotarget.15484, 2017


    25. 2016



  25. In vivo bioluminescence tomography for monitoring breast tumor growth and metastatic spreading: comparative study and mathematical modeling
    S. Mollard, R. Fanciullino, S. Giacometti, C. Serdjebi, S. Benzekry, J. Ciccolini
    Scientific Reports, Volume 6, pp.36173, 2016

  26. Mathematical modeling of cancer immunotherapy and synergy with radiotherapy
    R. Serre, S. Benzekry, L. Padovani, C. Meille, N. André, J. Ciccolini, F. Barlési, X. Muracciole, and D. Barbolosi
    Cancer Research, Volume 76, Issue 17, pp. 4931–40, 10.1158/0008-5472.CAN-15-3567, 2016

  27. Modeling spontaneous metastasis following surgery: an in vivo-in silico approach
    S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, J.M.L. Ebos
    Cancer Research, Volume 76, Issue 3, pp. 535-547, 10.1158/0008-5472.CAN-15-1389, 2016


    28. 2015



  28. Computational modelling of metastasis development in renal cell carcinoma
    E. Baratchart, S. Benzekry*, A. Bikfalvi*, T. Colin*, L.S. Cooley, R. Pineau, E. Ribot, O. Saut, W. Souleyreau, * = joint supervising authors
    PLoS Computational Biology, Volume 11, Issue 11, e1004626, hal, 2015

  29. Metronomics reloaded: theoretical models bringing chemotherapy into the era of precision medicine
    S. Benzekry+, E. Pasquier+, D. Barbolosi, B. Lacarelle, F. Barlesi, N. Andre and J. Ciccolini
    Seminars in Cancer Biology, Volume 35, pp. 53-61, 10.1016/j.semcancer.2015.09.002, 2015

  30. Design Principles for Cancer Therapy guided by changes in complexity of Protein-Protein Interaction Networks
    S. Benzekry , J.A. Tuszynski, E.A. Rietman, G.L. Klement
    Biology Direct, Volume 10, Issue 32, 2015

  31. Host Age is a Systemic Regulator of Gene Expression Impacting Cancer Progression
    A. Beheshti, S. Benzekry, J.T. MacDonald, L. Ma, M. Peluso, P. Hahnfeldt, L. Hlatky
    Cancer Research, Volume 75, Issue 6, pp. 1134-43, 2015


    32. 2014



  32. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth
    S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky, P. Hahnfeldt
    PLoS Computational Biology, Volume 10, Issue 8, e1003800, 2014

  33. Global Dormancy of Metastases due to Systemic Inhibition of Angiogenesis
    S. Benzekry, A. Gandolfi, P. Hahnfeldt
    PLoS One, Volume 9, Issue 1, e84249, 2014



    34. 2013



  34. Maximum Tolerated Dose Versus Metronomic Scheduling in the Treatment of Metastatic Cancers
    S. Benzekry, P. Hahnfeldt
    Journal of Theoretical Biology, Volume 335, pp. 235-244, 2013


  35. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice
    F. Lignet, S. Benzekry, S. Wilson, F. Billy, O. Saut, M. Tod, B. You, A. Adda Berkane, S. Kassour, M.X. Wei, E. Grenier, B. Ribba
    Journal of Theoretical Biology, Volume 320, pp. 86-99, 2013


    36. 2012



  36. Modelling the impact of anticancer agents on metastatic spreading
    S. Benzekry, N. André, A. Benabdallah, J. Ciccolini, C. Faivre, F. Hubert and D. Barbolosi
    Mathematical Modeling of Natural Phenomena , Volume 7, Issue 1, pp. 306 - 336, 2012

  37. A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
    S. Benzekry, G. Chapuisat, J. Ciccolini, A. Erlinger and F. Hubert
    Comptes Rendus de l'Académie des Sciences - Mathématiques, Volume 350, Issue 1-2, pp. 23-28, 2012

  38. Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers
    S. Benzekry
    ESAIM: Mathematical Modelling and Numerical Analysis, Volume 46, Issue 2, pp. 207-237, hal, 2012.


    39. 2011



  39. Passing to the limit 2D-1D in a model for metastatic growth
    S. Benzekry
    Journal of Biological Dynamics, Volume 6, Suppl. Issue 1, pp. 19-30, hal, 2011

  40. Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis,
    S. Benzekry
    Journal of Evolution Equations Volume 11, Issue 1, pp. 187-213, hal, 2011

Book chapters, editorials, proceedings and protocols


  1. Mechanistic models for hematological toxicities: Small is beautiful
    L. Deyme, S. Benzekry, J. Ciccolini
    CPT: Pharmacometrics Syst Pharmacol, Volume 10, Issue 5, pp. 396-398, 2021

  2. Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: the PIONeeR and QUANTIC joint-projects
    J. Ciccolini, S. Benzekry, F. Barlesi
    British Journal of Cancer, 2020

  3. Prédiction de l’efficacité de l’immunothérapie dans le cancer bronchique à partir de données cliniques et biologiques simples : apport de l’intelligence artificielle
    M. Grangeon, S. Benzekry, S. Chaleat, P. Tomasini, D. Barbolosi, F. Barlesi, L. Greillier
    Revue des Maladies Respiratoires, Volume 12, Issue 1, pp. 217, hal, 2020

  4. Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess
    J. Ciccolini, N. Andre, D. Barbolosi, S. Benzekry, F. Barlesi
    Annals of Oncology, Volume 62, Issue 2, hal, 2019

  5. Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor.
    C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, J. ML Ebos, C. Poignard and S. Benzekry
    In G. Bebis, T. Benos, K. Chen, K. Jahn, & E. Lima (Eds.), (pp. 87–97). Presented at the Mathematical and Computational Oncology, Cham: Springer International Publishing, 2019

  6. Abstract 4264: Mathematical modeling of differential effects of Sunitinib on primary tumor and metastatic growth.
    C. Nicolo, M. Mastri, J. ML Ebos, S. Benzekry
    Cancer Research, Volume 78, Issue 13 (Supplement), 4264, 2018

  7. Etude de l’effet séquence bevacizumab/pemetrexed/cisplatine chez la souris porteuse de cancer du poumon non à petites cellules.
    A. Boyer, J. Ciccolini, C. Mascaux, D.C. Imbs, R. El Cheikh, F. Barlesi, and S. Benzekry
    Revue des Maladies Respiratoires, 34:A52, 2017

  8. Abstract 4529: Optimization of the sequence for the administration of bevacizumab in combination with pemetrexed and cisplatin in NSCLC : a pharmacology based in vivo study A., Boyer, D.C. Imbs, R.E. Cheikh, C. Mascaux, F. Barlesi, D. Barbolosi, S. Benzekry, and J. Ciccolini.
    Cancer Research, Volume 77, Issue 13 (Supplement), 4529, 2017

  9. Optimized radiotherapy protocols delay the malignant transformation of low-grade gliomas in-silico
    A. Henares-Molina, S. Benzekry, P. Lara, M. García-Rojo, V. Pérez-García, and A. Martínez-González
    Neuro-Oncology, 19 (suppl 3):iii12–iii12, 2017

  10. Les lois de la croissance tumorale
    S. Benzekry
    Bibliothèque Tangente, Hors-série Maths et Médecine, 2016

  11. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai.
    Pantziarka, P., Hutchinson, L., André, N., Benzekry, S., Bertolini, F., Bhattacharjee, A., et al.
    ecancermedicalscience, 10, 2016

  12. On the growth and dissemination laws in a mathematical model of metastatic growth
    S. Benzekry, J. ML Ebos
    ITM Web of Conferences, Volume 5, 10.1051/itmconf/20150500007, 2015

  13. Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support
    J. Ciccolini, S. Benzekry, B. Lacarelle, D. Barbolosi and F. Barlési
    Proc Natl Acad Sci USA, Volume 112, Issue 27, 10.1073/pnas.1506689112, 2015

  14. Capturing the Driving Role of Tumor-Host Crosstalk in a Dynamical Model of Tumor Growth
    S. Benzekry, A. Beheshti, P. Hahnfeldt, L. Hlatky
    bio-protocol, Volume 5, Issue 21, e1644, hal, 2015

  15. Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxic modalities: application to the bevacizumab-paclitaxel association in breast cancer models S. Mollard, S. Benzekry, S. Giacometti, C. Faivre, F. Hubert, J. Ciccolini and D. Barbolosi.
    Cancer Research, Volume 74, Issue 19 (Supplement), 3677, 2014

  16. A Mathematical Model for Growing Metastases on Oncologists’s Service
    D. Barbolosi, A. Benabdallah, S. Benzekry, J. Ciccolini, C. Faivre, F. Hubert, F. Verga, B. You
    In Computational Surgery and Dual Training, Springer New York, pp. 331-338, 2014

  17. A mathematical model of systemic inhibition of angiogenesis in metastatic development
    S. Benzekry, A. Gandolfi, P. Hahnfeldt
    ESAIM: Proceedings, Volume 45, pp. 75-87, 2014

Foreign research visits

Fall 2016. Short sabbatical at the Roswell Park Cancer Institute to work with John ML Ebos, Buffalo, NY, USA.

September 2015. Invited researcher in the Môlab to work with Alicia Martinez-Gonzalez and Victor Pérez-Garcia, Ciudad Real, Spain.

January 2012 - November 2012. Postdoc at the Center of Cancer and Systems Biology, Boston, USA.

May 2011. Instituto di Analisi dei Sistemi ed Informatica ''Antonio Ruberti'', Consiglio Nazionale delle Ricerche. Research visit with Alberto Gandolfi and collaboration with Alberto d'Onofrio, from the European Institute of Oncology from Milan. Rome, Italy.

March - June 2007. Master 2’s intership in the mathematical department of the Polytechnical University of Catalonia : Exploration of deterministics and stochastics neuronal reds. Barcelona, Spain.


Invited talks


  1. May, 2022. 8th international conference on Systems Biology of Mammalian Cells: From Systems Medicine towards Digital Health, Heidelberg, Germany

  2. April, 2022. Quantitative systems pharmacology conference, Leiden, The Netherlands

  3. March, 2022. MI Day " Immunotherapies & Lung Cancer : predictive biomarkers from The PIONeeR Project ", Marseille, France

  4. January, 2022. Workshop on tissue growth and movement. Poincaré institute, Paris, France

  5. October, 2021. Multidisciplinary Approaches in Cancer Research. Sophia Antipolis, France

  6. June, 2021. Annual seminar of the regional Canceropole Provence-Alpes Cote d'Azur. COMPO: COMPutational pharmacology and clinical Oncology.

  7. June, 2021. Mini-symposium "Mathematical approaches to advance clinical studies in oncology ", Society of Mathematical Biology annual Conference.(online). Quantitative modeling of metastasis: cancer at the organism scale. (Slides)

  8. December, 2020. Workshop on Mathematical modelling in the machine learning era. Göteborg, Sweden (online conference).

  9. May, 2020, CIMPA Research Summer School on Mathematical models applied to molecular dynamics and oncology. Santiago de Cuba, Cuba.

  10. April 2020, 10th European Lung Cancer Congress (ELCC). Geneva, Switzerland.

  11. January, 2020, Second philosophy of cancer workshop. Quantitative modeling of metastasis: cancer at the organism scale. Bordeaux, France. (Slides)

  12. July 2019, International Society of Pharmacometrics (ISoP) workshop. Paris, France. (Slides)

  13. May 2019, Masterclass Mathematiques appliquees CEPS Mathematiques Des Sciences du Vivant, CIRM, Marseille, France. Data-driven mechanistic modeling of metastasis: cancer at the organism scale.

  14. May 2019, NCI Mathematical Oncology Meeting, Portland, USA. Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer.(Slides)

  15. May 2019, RITS conference (Recherche en Imagerie et Technologies pour la Sante) of the French Society of Biomedical Engineering (SFGBM), Tours, France. Data-driven mechanistic modeling of metastasis: cancer at the organism scale. (Slides)

  16. November 2018, Mathematical Challenges in the Analysis of Continuum Models for Cancer Growth, Evolution and Therapy, Oaxaca, Mexico. (Slides)

  17. July 2018, Mathematical perspectives in the biology and therapeutics of cancer, Marseille, France. (Slides)

  18. July 2018, Annual Workshop on Mathematics in Medicine, Wolfgang Pauli Institute, Vienna, Austria. (Slides)

  19. June 2018, 3rd Mathematical Biology Modelling Days, Besançon, France. (Slides)

  20. February 2018, CMM-Fields-Inria Workshop on Mathematics for Medicine, Toronto, Canada.

  21. January 2018, Conference on Statistics and Health, Toulouse, France.

  22. December 2017, Mathematical methods and modeling of biophysical phenomena. Mathematical modeling and prediction of metastasis. Rio de Janeiro, Brazil.

  23. September 2017, Première session du GDR MAMOVI. Mathematical Modeling and Prediction of Clinical Brain Metastases in Non-Small Cell Lung Cancer. Lyon, France

  24. June 2017, XXV Congreso de ecuaciones diferenciales y aplicaciones / XV congreso de matematica aplicada, Optimization of the timing of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by a mathematical model. Cartagena, Spain.

  25. May 2016, Metronomics @ Mumbai. Mathematical modeling of chemotherapy scheduling. Mumbai, India.

  26. December 2015, Present challenges of mathematics in oncology and biology of cancer. Marseille, France.

  27. November 2015, Dynamique et contrôle des croissances tumorales, Rouen, France.

  28. November 2015, Contrôle des EDP et applications , Marseille, France.

  29. October 2015, Journées du Groupe de Métabolisme et Pharmacocinétique , Paris, France.

  30. June 2015, Micro and Macro Systems in Life Sciences (MMSLS 2015), Bedlewo, Poland.

  31. March 2015, Workshop on hybrid and multiscale modelling in cell and cell population biology , Laboratoire Jacques-Louis Lions. Combined in vivo and in silico quantitative modeling of post-surgery metastatic development. Paris, France.

  32. March 2015, Mathematical Methods and Modeling of Biophysical Phenomena, Cabo Frio, Rio de Janeiro, Brazil.

  33. January 2015, 36th EORTC PAMM Winter meeting , Marseille, France.

  34. October 2014, Autumn School by Japanese and French Mathmaticians . Mathematical modeling of tumor growth and metastatic spread. Data, theories and predictions. Osaka, Japan.

  35. July 2014, 10th AIMS Conference on Dynamical Systems, Differential Equations and Applications . A mathematical model of systemic inhibition of angiogenesis in metastatic development. Madrid, Spain.

  36. November 2013, French-Mexican Meeting on Industrial and Applied Mathematics, Villahermosa, México. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth

  37. May 2013, Bi-annual congress of the SMAI. Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics. Seignosse, France.

  38. March 2013, Workshop on Mathematical Methods and Modeling of Biophysical Phenomena, Cabo Frio, Brazil. Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics

  39. July 2012, 2nd Annual Workshop on Cancer Systems Biology — Tumor Metronomics: Timing and Dose Level Dynamics, Center for Cancer and Systems Biology, Boston. Mathematical modeling of metastatic development and scheduling optimization of anti-cancerous therapies

  40. March 2012, Thematic school : "Present challenges of mathematics in oncology and biology of cancer", CIRM, Marseille. A modeling approach for therapies in metastatic cancers

  41. October 2011, Journées du Groupe de Métabolisme et Pharmacocinétique. Paris. Poster and Oral communication, Biomathematical modeling for description of metastatic processes and optimization of combined anti-angiogenic + cytotoxic therapies.

  42. July 2011, Workshop on Systems Biology of Tumor Dormancy. St. Elizabeth's Medical Center, Boston USA. A modelling approach for therapies in metastatic cancers.

  43. July 2011, 7th Congrès International Congress on Industrial and Applied Mathematics - ICIAM 2011, Vancouver. Mathematical modeling of the metastatic process and optimization of anti-cancerous therapies.

  44. May 2011, ``Emergence'' day of the Institut Gustave Roussy (IGR).Un exemple de modélisation du processus métastatique. Paris, France.

  45. June 2010, CANUM 2010, A model of metastatic growth under angiogenic control. Gironde, France.

  46. May 2010, AIMS Dresde. Modeling and mathematical analysis of metastatic growth under angiogenic control. Dresden, Germany

  47. March 2010, 2nd Workshop on Metronomic Anti-Angiogenic Chemotherapy in Paediatric Oncology. Mathematical modeling of MTD and metronomic temozolomide. Marseille, France.

Seminars (invited)


  1. February, 2022. Seminar in the bioinformatics group of the CRCM.

  2. October, 2021. Seminar at the Center for Cancer Research of Marseille. Mechanistic learning : combining mechanistic modeling and statistical learning to predict outcome in clinical oncology. Marseille, France

  3. June 2021, Seminar at the Centre de recherches en cancérologie de Toulouse (CRCT). Quantitative modeling of metastasis: cancer at the organism scale.

  4. May 2021, Seminar at the pharmacometrics group of Merck. COMPO - COMPutational pharmacology and clinical Oncology: Optimization of therapeutic strategies by mechanistic and statistical modeling.

  5. Apr 2021, Seminar of the Pharma - Informatics Unit of the Athena research group, Athens, Greece. COMPO - COMPutational pharmacology and clinical Oncology.

  6. Mar 2021, Applied statistics seminar of the mathematics department. Marseille, France. COMPO - COMPutational pharmacology and clinical Oncology.

  7. Jan 2021, Biomathematics seminar of the mathematics department. Marseille, France. COMPO - COMPutational pharmacology and clinical Oncology.

  8. June 2019, Seminar in the Novartis pharmacometrics department. Basel, Switwerland. Artificial intelligence and machine learning in oncology: myths and reality.

  9. May 2019, Biomedicum Helsinki Seminar (Invitation by Sampsa Hautaniemi), Faculty of Medicine, Helsinki, Finland.

  10. May 2019, Seminaire phases I en oncologie, Marseille, France. Old concept, new name? l’intelligence artificielle en oncologie.

  11. November 2018, Probability and Statistics seminar, Institut Elie Cartan de Lorraine, Nancy, France.

  12. February 2018, Seminar at the Roswell Park Cancer Institute (Invitation by Dr. J. Ebos), Buffalo, USA.

  13. December 2017, Seminar at the Rappaport Faculty of Medicine of the Technion Israel Institute of Technology (invitation by Yuval Shaked). Contributions in Mathematical Oncology: When Theory Meets Reality. Haifa, Israel.

  14. May 2017, Laboratoire d'Analyse Topologie et Probabilites, Institut de Mathematiques de Marseille. Mathematical Oncology: Theory Meets Reality. Marseille, France.

  15. November 2016, Integrated Mathematical Oncology Department, Moffitt Cancer Center.Mathematical Modeling of Metastasis: Theory Meets Reality. Tampa, Florida, USA.

  16. October 2016, Department of Genetics, Roswell Park Cancer Institute (invitation by John ML Ebos). Mathematical Modeling of Metastasis: Theory Meets Reality. Buffalo, NY, USA.

  17. October 2016, Robert Kerbel's laboratory at Sunnybrook Research Institute. Mathematical Modeling of Metastasis: Theory Meets Reality. Toronto, Canada.

  18. October 2016, Mathematics Department Colloquium, Ryerson University. Mathematical Modeling of Metastasis: Predicting the invisible. Toronto, Canada.

  19. May 2016, Seminar at the laboratory of Génétique, Immunothérapie, Chimie et Cancer of the University of Tours. Data-based mathematical modeling analysis of preclinical studies in oncology. Tours, France.

  20. January 2016, Seminar at the laboratoire d'imagerie biomédicale. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Paris, France.

  21. March 2014, Seminar at the Inria team Dracula. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Lyon, France.

  22. April 2013, Seminar of the ANEDP team . Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics. Orsay, France.

  23. February 2013, Seminar of the LATP, Marseille, France. A math walk in a biology lab

  24. November 2011, EDP seminar of the mathematics lab in Besançon. Modélisation et analyse mathématique de thérapies anti-cancéreuses pour les cancers métastatiques

  25. May 2011, Seminar at the Instituto di Analisi dei Sistemi ed Informatica ``Antonio Ruberti'', Rome. A modelling approach for the metastatic process.

  26. May 2010, Seminar Maths-Bio of the university Lyon 1. Modeling and mathematical analysis of metastatic growth under angiogenic control. Lyon, France

Accepted oral communications


  1. December 2020, Workshop on cancer adaptive therapy models. Examples of pharmacometrics studies in preclinical and clinical oncology: mathematical models in concrete therapeutic applications. Moffitt Cancer Center, Tampa, Florida, USA (online conference). (Slides). (Youtube video)

  2. August 2020, Virtual Physiological Human 2020 (VPH2020), Paris, France. Descriptive and prognostic value of a computational model of metastasis in high-risk neuroblastoma. Oral

  3. June 2019, Population Approach Group meeting in Europe (PAGE), Stockholm, Sweden. Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer. Oral

  4. June 2019, Population Approach Group meeting in Europe (PAGE), Stockholm, Sweden. Machine learning combined to mechanistic modeling of differential effects of neo-adjuvant Sunitinib on primary tumor and metastatic growth. Oral (senior author, first author and speaker C. Nicolo)

  5. August 2018, 17th Biennial Congress of the Metastasis Research Society, Princeton, NJ, USA. A biologically-based mathematical model for prediction of metastatic relapse. Poster.

  6. July 2018, Mathematical perspectives in the biology and therapeutics of cancer, Marseille, France. Improving intra-tumor drug distribution of anti-cancer nanoparticles by data-informed mathematical modeling. Oral (senior author, first author C. Vaghi).

  7. June 2018, Data science summer school, Polytechnique, Palaiseau, France. Improving intra-tumor drug distribution of anti-cancer nanoparticles by data-informed mathematical modeling. Poster (senior author, first author C. Vaghi. Won the best poster award)

  8. June 2018, Data science summer school, Polytechnique, Palaiseau, France. Poster

  9. May 2018, Population Approach Group in Europe (PAGE) meeting, Montreux, Switzerland. Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin. Poster (co-senior author with J. Mochel, first author B. Schneider).

  10. April 2018, Annual meeting of the AACR, Chicago, USA. Mathematical modeling of differential effects of Sunitinib on primary tumor and metastatic growth. Poster (senior author, first author C. Nicolo).

  11. March 2017, 38th EORTC-PAMM Winter meeting, Split, Croatia. Optimization of the timing of sequential administration of bevacizumab plus cytotoxics in NSCLC by a mathematical model.

  12. October 2015, Journées du cancéropôle Grand Sud-Ouest , Bordeaux, France. Poster. Modeling spontaneous metastasis following surgery: an in vivo-in silico approach

  13. June 2015, Mathematical Methods in Systems Biology, Dublin, Ireland.

  14. June 2014, European Conference on Mathematical and Theoretical Biology , Göteborg, Sweden. Metastatic dynamics, systemic inhibition of angiogenesis and implications for surgery

  15. June 2014, International Tumor Dormancy Symposium , Lille, France. Metastatic dynamics and systemic inhibition of angiogenesis. Implications for dormancy and surgery (Poster)

  16. February 2014, Demonstration during the inria-industry meeting, Lyon, France. Mathematical Models in Preclinical Cancer Research

  17. January 2014, Seminar at the ISPED. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth. Bordeaux, France.

  18. June 2011, 8th European Conference on Mathematical and Theoretical Biology - ECMTB 2011 and Annual Meeting of The Society for Mathematical Biology, Kraków. Optimal schedules for therapies in metastatic cancers .

  19. May 2010, CMPD 3, Bordeaux. Modeling and mathematical analysis of metastatic growth under angiogenic control.

  20. November 2009, Conference of biomathematics et biomechanics, Tozeur, Tunisie. Presentation of a poster.

  21. August 2009, CEMRACS. Asymptotic behavior of the solutions of the renewal equation and Angiogenesis modeling.

  22. June 2009, Bucolic days of the student's seminar of the LATP.

  23. November 2008, Workgroup Maths-Cancer of Marseille. About the article "A theoretical study of the response of vascular tumours to different types of chemotherapy" de J. Panovska, H. M. Byrne et P. K. Maini.

Participation to conferences and summer schools

6-8 June 2011, Biomat 2011, Perspectives in Mathematics and Life Sciences.

3-4 Février 2011, Journées Louis Antoine "Nonlocal equations and population adaptive dynamics".

2 December 2010. Thematic day "Models and imaging in oncology", Paris, France.

30 November - 1er December 2009. Symposium "Health and complex systems" of the Entretiens Jacques Cartier, Lyon, France.

20-23 November 2009. Conference of biomathématics et biomechanics, Tozeur, Tunisie.

20 July - 28 August 2009. CEMRACS'09 Mathematical modeling in Medicine. Project Angio. CIRM, Marseille, France.

2 - 13 February 2009. Advanced courses and conferences in mathematical biology : modeling and differential equations. CRM, Barcelone, Espagne.

18 - 19 December 2008. Pharmacokinetics and pharmacodynamics of anticancerous drugs : resistances and synergies. Centre de recherche des cordeliers, Paris.